As a Free StocksGuide user, you can view scores for all 7,053 stocks worldwide.
16 Analysts have issued a Cabaletta Bio Inc forecast:
16 Analysts have issued a Cabaletta Bio Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -158 -158 |
40%
40%
|
|
| EBIT (Operating Income) EBIT | -163 -163 |
42%
42%
|
|
| Net Profit | -159 -159 |
52%
52%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
| Head office | United States |
| CEO | Steven Nichtberger |
| Employees | 163 |
| Founded | 2017 |
| Website | www.cabalettabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


